All In Biotech

Drug Trial Radar · NCT06942910

A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

A Multicentre, Randomised, Double-blind, Active-Controlled, 2-arm Parallel-group Treatment, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

224

Actual

Start

May 7, 2025

Primary completion

Sep 26, 2026

Study completion Sep 26, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants with Chronic Kidney Disease and High Proteinuria

Conditions

  • Chronic Kidney Disease With High Proteinuria

Interventions

  • Zibotentan/DapagliflozinDrug

    Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to

  • DapagliflozinDrug

    Participants will receive monotherapy dapagliflozin as per the arms they are randomized to

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baselineTime frame: At Week 12

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Aramil, Russia

  • Research Site

    Izhevsk, Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Orenburg, Russia

  • Research Site

    Perm, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saratov, Russia

  • Research Site

    Saratov, Russia

  • Research Site

    Ulyanovsk, Russia

  • Research Site

    Yaroslavl, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.